Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?

European Urology, Supplements

Volumn 7, Issue 11, 2008, Pages 680-689

  Speakman, Mark J ^a  

^a MUSGROVE PARK HOSPITAL   (United Kingdom)

Author keywords

Acute urinary retention; Aetiology; Benign prostatic hyperplasia; Pathogenesis; Progression; Quality of life; Treatment

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; DUTASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INFLAMMATION; LOWER URINARY TRACT SYMPTOM; MEDICAL DECISION MAKING; NONHUMAN; PATHOGENESIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYMPTOMATOLOGY; URINE RETENTION;

EID: 52149093001     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.08.003     Document Type: Review

References (46)

1. Berry S.J., Coffey D.S., Walsh P.C., and Ewing L.J. The development of human benign prostatic hyperplasia with age. J Urol 132 (1984) 474-479
2. Chute C.G., Panser L.A., Girman C.J., et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 150 (1993) 85-89
3. Speakman M.J. The causes of lower urinary tract symptoms in patients. Drugs Today 37 Suppl D (2001) 3-6
4. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
5. Price D. Potential mechanisms of action of superselective α1-adrenoceptor antagonists. Eur Urol 40 Suppl 4 (2001) 5-11
6. Levin R.M., Levin S.S., Zhao Y., and Buttyan R. Cellular and molecular aspects of bladder hypertrophy. Eur Urol 32 Suppl 1 (1997) 15-21
7. Elbadawi A., Diokno A.C., and Millard R.J. The aging bladder: morphology and urodynamics. World J Urol 16 Suppl 1 (1998) S10-34
8. Schwinn D.A., and Michelotti G.A. alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int 85 Suppl 2 (2000) 6-11
9. Andersson K.E. Storage and voiding symptoms: pathophysiologic aspects. Urology 62 Suppl 2 (2003) 3-10
10. Kim J.C., Yoo J.S., Park E.Y., Hong S.H., Seo S.I., and Hwang T.K. Muscarinic and purinergic receptor expression in the urothelium of rats with detrusor overactivity induced by bladder outlet obstruction. BJU Int 101 (2008) 371-375
11. Mukerji G., Yiangou Y., Grogono J., et al. Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 176 (2006) 367-373
12. O'Reilly B.A., Kosaka A.H., Chang T.K., Ford A.P., Popert R., and McMahon S.B. A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. BJU Int 87 (2001) 617-622
13. Levin R.M., Haugaard N., O'Connor L., et al. Obstructive response of human bladder to BPH vs. rabbit bladder response to partial outlet obstruction: a direct comparison. Neurourol Urodyn 19 (2000) 609-629
14. Tubaro A., and Miano L. Managing the consequences of obstruction. Eur Urol Suppl 1 9 (2002) 21-27
15. Jacobsen S.J., Girman C.J., Guess H.A., Rhodes T., Oesterling J.E., and Lieber M.M. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 155 (1996) 595-600
16. Roberts R.O., Jacobsen S.J., Jacobson D.J., Rhodes T., Girman C.J., and Lieber M.M. Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol 163 (2000) 107-113
17. Rhodes T., Girman C.J., Jacobsen S.J., Roberts R.O., Guess H.A., and Lieber M.M. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 161 (1999) 1174-1179
18. Jacobsen S.J., Jacobson D.J., Girman C.J., et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 158 (1997) 481-487
19. Lee A.J., Garraway W.M., Simpson R.J., Fisher W., and King D. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol 34 (1998) 325-332
20. Dobrovits M., Chaudry A., Anagnostou T., et al. A longitudinal prospective study of men with mild symptoms of BOO treated with watchful waiting over 4 years. Eur Urol Suppl 2 1 (2003) 26 abstract 96
21. Meigs J.B., Barry M.J., Giovannucci E., Rimm E.B., Stampfer M.J., and Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals followup study. J Urol 162 (1999) 376-382
22. McConnell J.D., Roehrborn C.G., Bautista O.M., et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349 (2003) 2387-2398
23. Khastgir J., Khan A., and Speakman M. Acute urinary retention: medical management and the identification of risk factors for prevention. Nat Clin Pract Urol 4 (2007) 422-431
24. Kolman C., Girman C.J., Jacobsen S.J., and Lieber M.M. Distribution of post-void residual urine volume in randomly selected men. J Urol 161 (1999) 122-127
25. Crawford E.D., Wilson S.S., McConnell J.D., et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175 (2006) 1422-1426
26. Roehrborn C.G., McConnell J.D., Lieber M.M., et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 53 (1999) 473-480
27. Marberger M.J., Andersen J.T., Nickel J.C., et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention: combined experience from three large multinational placebo-controlled trials. Eur Urol 38 (2000) 563-568
28. Nickel J.C., Downey J., Young I., and Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 84 (1999) 976-981
29. Kramer G., Mitteregger D., and Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?. Eur Urol 51 (2007) 1202-1216
30. Roehrborn C.G., Kaplan S.A., Noble W.D., et al. The impact of acute or chronic inflammation in baseline biopsy on the risk of clinical progression of BPH: results from the MTOPS study. J Urol 173 Suppl (2005) 346 abstract 1277
31. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. In press. doi:10.1016/j.eururo.2007.11.026.
32. St Sauver J.L., Jacobson D.J., McGree M.E., Girman C.J., Lieber M.M., and Jacobsen S.J. Longitudinal association between prostatitis and development of benign prostatic hyperplasia. Urology 71 (2008) 475-479
33. Mishra V.C., Allen D.J., Nicolaou C., et al. Does intraprostatic inflammation have a role in the pathogenesis and progression of benign prostatic hyperplasia?. BJU Int 100 (2007) 327-331
34. St Sauver J.L., Jacobson D.J., McGree M.E., Lieber M.M., and Jacobsen S.J. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 164 (2006) 760-768
35. Emberton M. Definition of at-risk patients: dynamic variables. BJU Int 97 Suppl 2 (2006) 12-15
36. Emberton M., Elhilali M., Matzkin H., et al. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. Urology 66 (2005) 316-322
37. Vallancien G., Emberton M., Alcaraz A., et al. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. BJU Int 101 (2008) 847-852
38. Slawin K.M., and Kattan M.W. The use of nomograms for selecting BPH candidates for dutasteride therapy. Rev Urol 6 Suppl 9 (2004) S40-S45
39. Mullins C., Lucia M.S., Hayward S.W., et al. A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium. J Urol 179 (2008) 1243-1256
40. Chapple C.R. The total approach in lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) management: introduction and conclusions. Eur Urol Suppl 2 7 (2003) 1-5
41. Girman C.J., Epstein R.S., Jacobsen S.J., et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 44 (1994) 825-831
42. Batista-Miranda J.E., Molinuevo B., and Pardo Y. Impact of lower urinary tract symptoms on quality of life using Functional Assessment Cancer Therapy scale. Urology 69 (2007) 285-288
43. Welch G., Weinger K., and Barry M.J. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-Up Study. Urology 59 (2002) 245-250
44. Sells H., Donovan J., Ewings P., and MacDonagh R.P. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement. BJU Int 85 (2000) 440-445
45. Trueman P., Hood S.C., Nayak U.S., and Mrazek M.F. Prevalence of lower urinary tract symptoms and self-reported diagnosed 'benign prostatic hyperplasia', and their effect on quality of life in a community-based survey of men in the UK. BJU Int 83 (1999) 410-415
46. McVary K.T. BPH: epidemiology and comorbidities. Am J Manag Care 12 (2006) S122-S128